Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia
NCT ID: NCT01524302
Last Updated: 2016-04-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
12 participants
INTERVENTIONAL
2012-02-29
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization
NCT00236834
Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia
NCT00429975
Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia
NCT01666743
A Study of the Safety and Effectiveness of Levofloxacin Compared With Ceftriaxone Sodium or Cefuroxime Axetil in the Treatment of Adults With Pneumonia
NCT00257049
Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia
NCT00081575
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Levofloxacin
Pharmacodynamics
Levofloxacin
750 mg QD
Ceftaroline
Pharmacodynamics
Ceftaroline
600 mg Q12h
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ceftaroline
600 mg Q12h
Levofloxacin
750 mg QD
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All patients will have a creatinine clearance (CrCl) \>50 ml/min.
Exclusion Criteria
* allergy to penicillin/cephalosporin antibiotics,
* allergy to fluoroquinolones,
* renal or hepatic failure, or have received an antimicrobial in past 96h.
* Patients who require antibiotics other than the study drugs will also be excluded.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Forest Laboratories
INDUSTRY
Gary E. Stein, Pharm.D.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gary E. Stein, Pharm.D.
Professor of Medicine and Pharmacology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gary E Stein, Pharm.D.
Role: PRINCIPAL_INVESTIGATOR
Michigan State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sparrow Hospital
Lansing, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TEF-MD-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.